S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58

MediWound (MDWD) Stock Forecast, Price & News

-0.01 (-0.55%)
(As of 05/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
21,941 shs
Average Volume
120,435 shs
Market Capitalization
$59.54 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MediWound logo

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.


See More Headlines

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$23.76 million
Book Value
$0.06 per share


Net Income
$-13.55 million
Pretax Margin




Free Float
Market Cap
$59.54 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.73 out of 5 stars

Medical Sector

871st out of 1,418 stocks

Medicinals & Botanicals Industry

7th out of 21 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound
or view top-rated stocks.

Are investors shorting MediWound?

MediWound saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 54,800 shares, a decline of 30.6% from the April 15th total of 79,000 shares. Based on an average daily volume of 116,100 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the shares of the company are short sold.
View MediWound's Short Interest

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for MediWound

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. MediWound had a negative net margin of 57.03% and a negative trailing twelve-month return on equity of 3,540.43%. During the same period in the previous year, the firm earned ($0.10) EPS.
View MediWound's earnings history

What price target have analysts set for MDWD?

4 brokerages have issued 1-year price targets for MediWound's shares. Their forecasts range from $6.50 to $8.00. On average, they expect MediWound's stock price to reach $7.13 in the next twelve months. This suggests a possible upside of 295.8% from the stock's current price.
View analysts' price targets for MediWound
or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?
MediWound's management team includes the following people:
  • Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 50, Pay $497k)
  • Prof. Lior Rosenberg M.D., Co-Founder & Chief Medical Technology Officer (Age 76, Pay $398k)
  • Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 48, Pay $309k)
  • Mr. Yaron Meyer Adv., Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $240k)
  • Dr. Ety Klinger, Chief R&D Officer (Age 60, Pay $344k)
  • Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 65)
What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.13%), Meitav Dash Investments Ltd. (0.93%), Acadian Asset Management LLC (0.08%), Warberg Asset Management LLC (0.07%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are selling MediWound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Simplex Trading LLC.

Which institutional investors are buying MediWound stock?

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Warberg Asset Management LLC, and Sargent Investment Group LLC.

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $1.80.

How much money does MediWound make?

MediWound has a market capitalization of $59.54 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13.55 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 77 workers across the globe.

What is MediWound's official website?

The official website for MediWound is www.mediwound.com.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972779714100, via email at [email protected], or via fax at 972-77-971-4111.

This page was last updated on 5/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.